JP2015512263A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512263A5 JP2015512263A5 JP2015503650A JP2015503650A JP2015512263A5 JP 2015512263 A5 JP2015512263 A5 JP 2015512263A5 JP 2015503650 A JP2015503650 A JP 2015503650A JP 2015503650 A JP2015503650 A JP 2015503650A JP 2015512263 A5 JP2015512263 A5 JP 2015512263A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- seq
- glycoprotein
- composition
- lentiviral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 claims description 163
- 102000036639 antigens Human genes 0.000 claims description 163
- 108091007433 antigens Proteins 0.000 claims description 163
- 238000000034 method Methods 0.000 claims description 65
- 108090000288 Glycoproteins Proteins 0.000 claims description 34
- 102000003886 Glycoproteins Human genes 0.000 claims description 34
- 108091033319 polynucleotide Proteins 0.000 claims description 31
- 239000002157 polynucleotide Substances 0.000 claims description 31
- 102000040430 polynucleotide Human genes 0.000 claims description 31
- 102100034349 Integrase Human genes 0.000 claims description 30
- 241000700605 Viruses Species 0.000 claims description 28
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 24
- 239000002245 particle Substances 0.000 claims description 23
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 claims description 18
- 210000004027 cell Anatomy 0.000 claims description 16
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 14
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 14
- 101710149136 Protein Vpr Proteins 0.000 claims description 14
- 108700004029 pol Genes Proteins 0.000 claims description 13
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims description 10
- -1 RAGE Proteins 0.000 claims description 10
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 108700004026 gag Genes Proteins 0.000 claims description 9
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 8
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 8
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 8
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 8
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 8
- YINZYTTZHLPWBO-UHFFFAOYSA-N Kifunensine Natural products COC1C(O)C(O)C(O)C2NC(=O)C(=O)N12 YINZYTTZHLPWBO-UHFFFAOYSA-N 0.000 claims description 8
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 8
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims description 8
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims description 8
- 102000003425 Tyrosinase Human genes 0.000 claims description 8
- 108060008724 Tyrosinase Proteins 0.000 claims description 8
- 210000004443 dendritic cell Anatomy 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 8
- 102000037865 fusion proteins Human genes 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- OIURYJWYVIAOCW-VFUOTHLCSA-N kifunensine Chemical compound OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H]2NC(=O)C(=O)N12 OIURYJWYVIAOCW-VFUOTHLCSA-N 0.000 claims description 8
- 210000002307 prostate Anatomy 0.000 claims description 8
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 claims description 8
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 claims description 6
- 241000701806 Human papillomavirus Species 0.000 claims description 6
- 108010061833 Integrases Proteins 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 claims description 6
- 101150114242 SAMHD1 gene Proteins 0.000 claims description 6
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000002603 mannosidase inhibitor Substances 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 101150088264 pol gene Proteins 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 4
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 4
- 108700012439 CA9 Proteins 0.000 claims description 4
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims description 4
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims description 4
- 108020004705 Codon Proteins 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 4
- 208000000655 Distemper Diseases 0.000 claims description 4
- 101150029707 ERBB2 gene Proteins 0.000 claims description 4
- 241001115402 Ebolavirus Species 0.000 claims description 4
- 241000709661 Enterovirus Species 0.000 claims description 4
- 241000991587 Enterovirus C Species 0.000 claims description 4
- 241000710831 Flavivirus Species 0.000 claims description 4
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 4
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 4
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims description 4
- 102100028092 Homeobox protein Nkx-3.1 Human genes 0.000 claims description 4
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 4
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims description 4
- 101000578249 Homo sapiens Homeobox protein Nkx-3.1 Proteins 0.000 claims description 4
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 4
- 101000628547 Homo sapiens Metalloreductase STEAP1 Proteins 0.000 claims description 4
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 4
- 241000713340 Human immunodeficiency virus 2 Species 0.000 claims description 4
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 4
- 241001115401 Marburgvirus Species 0.000 claims description 4
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims description 4
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 4
- 102000003735 Mesothelin Human genes 0.000 claims description 4
- 108090000015 Mesothelin Proteins 0.000 claims description 4
- 102100026712 Metalloreductase STEAP1 Human genes 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 241001631646 Papillomaviridae Species 0.000 claims description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 4
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 claims description 4
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 claims description 4
- 241000710778 Pestivirus Species 0.000 claims description 4
- 241000709664 Picornaviridae Species 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 101710132594 Protein E6 Proteins 0.000 claims description 4
- 101710132595 Protein E7 Proteins 0.000 claims description 4
- 241000711798 Rabies lyssavirus Species 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 241000702263 Reovirus sp. Species 0.000 claims description 4
- 108091027981 Response element Proteins 0.000 claims description 4
- 241000702670 Rotavirus Species 0.000 claims description 4
- 241000710960 Sindbis virus Species 0.000 claims description 4
- 108010002687 Survivin Proteins 0.000 claims description 4
- 108010017842 Telomerase Proteins 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims description 4
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims description 4
- 230000002457 bidirectional effect Effects 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 230000002950 deficient Effects 0.000 claims description 4
- 230000004041 dendritic cell maturation Effects 0.000 claims description 4
- 108010018033 endothelial PAS domain-containing protein 1 Proteins 0.000 claims description 4
- 235000013922 glutamic acid Nutrition 0.000 claims description 4
- 239000004220 glutamic acid Substances 0.000 claims description 4
- 108010028403 hemagglutinin esterase Proteins 0.000 claims description 4
- 108090000237 interleukin-24 Proteins 0.000 claims description 4
- 102000003898 interleukin-24 Human genes 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 238000012737 microarray-based gene expression Methods 0.000 claims description 4
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 4
- 206010034674 peritonitis Diseases 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 230000008707 rearrangement Effects 0.000 claims description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 4
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 241000701161 unidentified adenovirus Species 0.000 claims description 4
- 241001529453 unidentified herpesvirus Species 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 101710150344 Protein Rev Proteins 0.000 claims description 3
- 241000710929 Alphavirus Species 0.000 claims description 2
- 108010029697 CD40 Ligand Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102100032937 CD40 ligand Human genes 0.000 claims description 2
- 241000701022 Cytomegalovirus Species 0.000 claims description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 108010002350 Interleukin-2 Proteins 0.000 claims description 2
- 108010065637 Interleukin-23 Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 108010002586 Interleukin-7 Proteins 0.000 claims description 2
- 108091092195 Intron Proteins 0.000 claims description 2
- 241000714474 Rous sarcoma virus Species 0.000 claims description 2
- 108700026226 TATA Box Proteins 0.000 claims description 2
- 239000004098 Tetracycline Substances 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 102000044159 Ubiquitin Human genes 0.000 claims description 2
- 108090000848 Ubiquitin Proteins 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 101150098622 gag gene Proteins 0.000 claims description 2
- 108010074108 interleukin-21 Proteins 0.000 claims description 2
- 102220036548 rs140382474 Human genes 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 229960002180 tetracycline Drugs 0.000 claims description 2
- 229930101283 tetracycline Natural products 0.000 claims description 2
- 235000019364 tetracycline Nutrition 0.000 claims description 2
- 150000003522 tetracyclines Chemical class 0.000 claims description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 2
- 102000012466 Cytochrome P450 1B1 Human genes 0.000 claims 2
- 108050002014 Cytochrome P450 1B1 Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 101000951392 Homo sapiens Alpha-1,6-mannosylglycoprotein 6-beta-N-acetylglucosaminyltransferase A Proteins 0.000 claims 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 2
- 241000785747 Mavirus Species 0.000 claims 2
- 102000003932 Transgelin Human genes 0.000 claims 2
- 108090000333 Transgelin Proteins 0.000 claims 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 229960004424 carbon dioxide Drugs 0.000 claims 2
- 235000011089 carbon dioxide Nutrition 0.000 claims 2
- 102000056313 human Mgat5 Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000890 antigenic effect Effects 0.000 claims 1
- 108010033547 Carbonic Anhydrase I Proteins 0.000 description 2
- 102100025518 Carbonic anhydrase 1 Human genes 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/436,472 US8323662B1 (en) | 2012-03-30 | 2012-03-30 | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
| US13/436,472 | 2012-03-30 | ||
| US201261666103P | 2012-06-29 | 2012-06-29 | |
| US61/666,103 | 2012-06-29 | ||
| US201261732756P | 2012-12-03 | 2012-12-03 | |
| US61/732,756 | 2012-12-03 | ||
| US201361789575P | 2013-03-15 | 2013-03-15 | |
| US61/789,575 | 2013-03-15 | ||
| PCT/US2013/034640 WO2013149167A1 (en) | 2012-03-30 | 2013-03-29 | Lentiviral vector particles having improved transduction efficiency for cells expressing dc- sign |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017254078A Division JP2018046860A (ja) | 2012-03-30 | 2017-12-28 | Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015512263A JP2015512263A (ja) | 2015-04-27 |
| JP2015512263A5 true JP2015512263A5 (enExample) | 2016-05-26 |
Family
ID=48096326
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503650A Withdrawn JP2015512263A (ja) | 2012-03-30 | 2013-03-29 | Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子 |
| JP2017254078A Withdrawn JP2018046860A (ja) | 2012-03-30 | 2017-12-28 | Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子 |
| JP2019234349A Pending JP2020072689A (ja) | 2012-03-30 | 2019-12-25 | Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017254078A Withdrawn JP2018046860A (ja) | 2012-03-30 | 2017-12-28 | Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子 |
| JP2019234349A Pending JP2020072689A (ja) | 2012-03-30 | 2019-12-25 | Ｄｃ−ｓｉｇｎを発現する細胞に対して改善された形質導入の有効性を有するレンチウイルスベクター粒子 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US10993999B2 (enExample) |
| EP (2) | EP2831095B1 (enExample) |
| JP (3) | JP2015512263A (enExample) |
| KR (1) | KR102070472B1 (enExample) |
| CN (1) | CN104583231B (enExample) |
| AU (1) | AU2013237900B2 (enExample) |
| BR (1) | BR112014024449A2 (enExample) |
| CA (1) | CA2868838C (enExample) |
| DK (1) | DK2831095T3 (enExample) |
| EA (1) | EA038702B1 (enExample) |
| ES (1) | ES2707288T3 (enExample) |
| IL (1) | IL234838B (enExample) |
| MX (1) | MX362699B (enExample) |
| NZ (1) | NZ700340A (enExample) |
| PT (1) | PT2831095T (enExample) |
| SG (1) | SG11201406162UA (enExample) |
| WO (1) | WO2013149167A1 (enExample) |
| ZA (1) | ZA201407174B (enExample) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015225867B2 (en) * | 2014-03-07 | 2020-02-06 | University Health Network | Methods and compositions for modifying the immune response |
| US20170196954A1 (en) | 2014-07-15 | 2017-07-13 | Immune Design Corp. | Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector |
| US10238741B2 (en) | 2014-10-10 | 2019-03-26 | The Trustees Of Columbia University In The City Of New York | Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof |
| WO2016057986A1 (en) * | 2014-10-10 | 2016-04-14 | The Trustees Of Columbia University In The City Of New York | Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof |
| CN104388387B (zh) * | 2014-11-18 | 2017-02-22 | 浙江大学 | 一种hiv‑1大量感染复制的单核巨噬细胞模型的构建方法 |
| CN104450784B (zh) * | 2014-11-18 | 2017-03-22 | 浙江大学 | 一种samhd1基因敲除细胞系的构建方法 |
| CN104587491A (zh) * | 2014-12-30 | 2015-05-06 | 天津大学 | SAMHD1-pLNCX2制备抗肿瘤药物的用途 |
| ES2945656T3 (es) | 2015-05-29 | 2023-07-05 | Japan Tobacco Inc | Inhalador de aroma sin combustión |
| CN108137670A (zh) | 2015-09-09 | 2018-06-08 | 免疫设计股份有限公司 | Ny-eso-1特异性tcr及其使用方法 |
| WO2017066570A1 (en) * | 2015-10-15 | 2017-04-20 | The University Of North Carolina At Chapel Hill | Methods and compositions for integration-defective lentiviral vectors |
| WO2017070167A1 (en) | 2015-10-20 | 2017-04-27 | The University Of North Carolina At Chapel Hill | Methods and compositions for modified factor ix fusion proteins |
| SG11201803546WA (en) * | 2015-11-09 | 2018-05-30 | Immune Design Corp | Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof |
| WO2017083356A1 (en) | 2015-11-09 | 2017-05-18 | Immune Design Corp. | A retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids |
| EP3907283A3 (en) * | 2015-11-19 | 2022-01-26 | Novartis AG | Buffers for stabilization of lentiviral preparations |
| AU2017223460A1 (en) | 2016-02-23 | 2018-09-13 | Immune Design Corp. | Multigenome retroviral vector preparations and methods and systems for producing and using same |
| IL310729A (en) | 2016-04-15 | 2024-04-01 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| WO2017181148A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
| CN106119196A (zh) * | 2016-06-24 | 2016-11-16 | 安徽未名细胞治疗有限公司 | 一种dc细胞的制备方法 |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| EP3872180A1 (en) | 2016-10-20 | 2021-09-01 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018148180A2 (en) | 2017-02-07 | 2018-08-16 | Immune Design Corp. | Materials and methods for identifying and treating cancer patients |
| WO2018170021A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
| IL268781B2 (en) | 2017-03-16 | 2025-09-01 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| US11732022B2 (en) | 2017-03-16 | 2023-08-22 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
| CN107557391A (zh) * | 2017-09-25 | 2018-01-09 | 山东信得科技股份有限公司 | 基于Nectin4受体的犬瘟热敏感细胞系建立方法及应用 |
| CN107760700B (zh) * | 2017-09-30 | 2020-11-06 | 武汉轻工大学 | β-甘露聚糖酶基因、重组表达载体、菌株、β-甘露聚糖酶及其制备方法及应用 |
| EA202090974A1 (ru) | 2017-10-18 | 2020-08-05 | Элпайн Иммьюн Сайенсиз, Инк. | Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы |
| CN107779474A (zh) * | 2017-11-02 | 2018-03-09 | 中国人民解放军南京军区福州总医院 | 一个表达乳头瘤病毒hpv16的e6和e7自剪切慢病毒载体 |
| WO2019136179A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| CN110819648B (zh) * | 2018-08-07 | 2022-01-28 | 北京惠大生物科技有限公司 | 感染有慢病毒的永生化dc细胞及其在杀伤表达mage-a3肿瘤细胞中的应用 |
| CA3110926A1 (en) * | 2018-08-28 | 2020-03-05 | Pharos Vaccine Inc. | Improved lentiviral vector |
| CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| PE20230494A1 (es) | 2020-05-08 | 2023-03-23 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras inhibidoras de april y baff y metodos de uso de las mismas |
| CN113846099B (zh) * | 2021-09-23 | 2022-04-22 | 中国农业科学院兰州兽医研究所 | 用于敲低猪SAMHD1基因表达的siRNA、试剂盒及其应用 |
| WO2024163805A1 (en) * | 2023-02-01 | 2024-08-08 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| CN120591214A (zh) * | 2025-07-02 | 2025-09-05 | 山东第一医科大学第二附属医院 | 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用 |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| US4569794A (en) | 1984-12-05 | 1986-02-11 | Eli Lilly And Company | Process for purifying proteins and compounds useful in such process |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4937190A (en) | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| EP0342926B1 (en) | 1988-05-17 | 1994-09-28 | Mycogen Plant Science, Inc. | Plant ubiquitin promoter system |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5298420A (en) | 1990-08-03 | 1994-03-29 | Tanox Biosystems, Inc. | Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface |
| TW279133B (enExample) | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| CA2145063A1 (en) | 1992-09-22 | 1994-03-31 | Cambridge Genetics Limited | Recombinant viruses displaying a nonviral polypeptide on their external surface |
| US6534051B1 (en) | 1992-11-20 | 2003-03-18 | University Of Medicine And Dentistry Of New Jersey | Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins |
| US5279552A (en) | 1993-01-11 | 1994-01-18 | Anton Magnet | Intradermal injection device |
| US5997501A (en) | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
| AU4594996A (en) | 1994-11-30 | 1996-06-19 | Chiron Viagene, Inc. | Recombinant alphavirus vectors |
| US5660835A (en) | 1995-02-24 | 1997-08-26 | East Carolina University | Method of treating adenosine depletion |
| WO1997005266A1 (en) | 1995-07-25 | 1997-02-13 | Introgene B.V. | Methods and means for targeted gene delivery |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5910434A (en) | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
| FR2747046B1 (fr) | 1996-04-05 | 1998-06-19 | Univ Paris Curie | Nouveaux vaccins issus de plasmovirus |
| EP0961830A1 (en) | 1997-01-29 | 1999-12-08 | Neurosearch A/S | EXPRESSION VECTORS AND METHODS FOR $i(IN VIVO) EXPRESSION OF THERAPEUTIC POLYPEPTIDES |
| US6432699B1 (en) | 1997-03-28 | 2002-08-13 | New York University | Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A |
| US6531123B1 (en) | 1997-05-01 | 2003-03-11 | Lung-Ji Chang | Lentiviral vectors |
| ZA988446B (en) | 1997-09-18 | 2000-03-22 | Res Dev Foundation | Production of vaccines using arthropod vectored viruses. |
| WO1999013905A1 (en) | 1997-09-18 | 1999-03-25 | The Trustees Of The University Of Pennsylvania | Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery |
| US6218181B1 (en) | 1998-03-18 | 2001-04-17 | The Salk Institute For Biological Studies | Retroviral packaging cell line |
| US7078483B2 (en) | 1998-04-29 | 2006-07-18 | University Of Southern California | Retroviral vectors including modified envelope escort proteins |
| EP1165842A4 (en) | 1999-03-16 | 2004-07-07 | Dana Farber Cancer Inst Inc | LENTIVIRAL VECTOR SYSTEM FOR LARGE QUANTITY SCREENING |
| DK1175497T3 (da) | 1999-04-14 | 2010-05-31 | Novartis Vaccines & Diagnostic | Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer |
| EP1046651A1 (en) | 1999-04-19 | 2000-10-25 | Koninklijke Universiteit Nijmegen | Composition and method for modulating dendritic cell-T interaction |
| WO2001016342A1 (en) | 1999-08-27 | 2001-03-08 | The Regents Of The University Of California | Use of lentiviral vectors for antigen presentation in dendritic cells |
| WO2001016324A2 (en) | 1999-08-31 | 2001-03-08 | Board Of Regents, The University Of Texas System | Methods and compositions of a novel serine protease inhibitor |
| PT1221968E (pt) | 1999-10-13 | 2010-04-16 | Novartis Vaccines & Diagnostic | Processo de obtenção de respostas imunes celulares de proteínas |
| US20020193740A1 (en) | 1999-10-14 | 2002-12-19 | Alchas Paul G. | Method of intradermally injecting substances |
| US6776776B2 (en) | 1999-10-14 | 2004-08-17 | Becton, Dickinson And Company | Prefillable intradermal delivery device |
| US7241275B2 (en) | 1999-10-14 | 2007-07-10 | Becton, Dickinson And Company | Intradermal needle |
| US6569143B2 (en) | 1999-10-14 | 2003-05-27 | Becton, Dickinson And Company | Method of intradermally injecting substances |
| US6494865B1 (en) | 1999-10-14 | 2002-12-17 | Becton Dickinson And Company | Intradermal delivery device including a needle assembly |
| US6627442B1 (en) | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
| EP1201750A1 (en) | 2000-10-26 | 2002-05-02 | Genopoietic | Synthetic viruses and uses thereof |
| CA2439620A1 (en) | 2001-03-02 | 2002-09-12 | Merck & Co., Inc. | Viral reporter particles |
| ATE439041T1 (de) | 2001-09-13 | 2009-08-15 | California Inst Of Techn | Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle |
| US7195916B2 (en) | 2001-09-13 | 2007-03-27 | California Institute Of Technology | Method for expression of small antiviral RNA molecules within a cell |
| EP1425400B1 (en) | 2001-09-13 | 2016-11-02 | California Institute Of Technology | Method for producing transgenic animals |
| US7737124B2 (en) | 2001-09-13 | 2010-06-15 | California Institute Of Technology | Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell |
| AU2002346399A1 (en) | 2001-11-14 | 2003-05-26 | Medical Instill Technologies, Inc. | Intradermal delivery device and method |
| DE60328361D1 (de) | 2002-02-04 | 2009-08-27 | Becton Dickinson Co | Vorrichtung und verfahren zur abgabe oder entnahme einer substanz durch die haut |
| US7115108B2 (en) | 2002-04-02 | 2006-10-03 | Becton, Dickinson And Company | Method and device for intradermally delivering a substance |
| US6780171B2 (en) | 2002-04-02 | 2004-08-24 | Becton, Dickinson And Company | Intradermal delivery device |
| US7047070B2 (en) | 2002-04-02 | 2006-05-16 | Becton, Dickinson And Company | Valved intradermal delivery device and method of intradermally delivering a substance to a patient |
| US6863884B2 (en) | 2002-05-01 | 2005-03-08 | Cell Genesys, Inc. | Pseudotyped retroviral vectors |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| DE60322070D1 (de) | 2002-08-16 | 2008-08-21 | Dept Of Medical Sciences Minis | Rekombinante bcg-vakzine |
| US7250251B2 (en) | 2002-09-09 | 2007-07-31 | The J. David Gladstone Institutes | Virion-based fusion assay |
| US20040234504A1 (en) | 2002-12-18 | 2004-11-25 | Verma Inder M. | Methods of inhibiting gene expression by RNA interference |
| US7090837B2 (en) | 2003-01-21 | 2006-08-15 | The Salk Institute For Biological Studies | Compositions and methods for tissue specific targeting of lentivirus vectors |
| US7556814B2 (en) | 2003-10-23 | 2009-07-07 | Karp Nelson M | Immunogenic compositions comprising UV-irradiated, psoralen-inactivated, desialated human immunodeficiency virus (HIV) devoid of CD55 and CD59 in the viral membrane |
| US7108679B2 (en) | 2004-03-11 | 2006-09-19 | Becton, Dickinson And Company | Intradermal syringe and needle assembly |
| WO2005113584A1 (en) | 2004-04-29 | 2005-12-01 | Board Of Regents, University Of Texas System | Methods and compositions comprising protein l immunoglobulin binding domains for cell-specific targeting |
| WO2005118802A2 (en) | 2004-06-03 | 2005-12-15 | The Regents Of The University Of California | Targeting pseudotyped retroviral vectors |
| FR2872170B1 (fr) | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| GB0417494D0 (en) | 2004-08-05 | 2004-09-08 | Glaxosmithkline Biolog Sa | Vaccine |
| WO2006031996A2 (en) | 2004-09-14 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Targeting viruses using a modified sindbis glycoprotein |
| WO2006130855A2 (en) | 2005-06-01 | 2006-12-07 | California Institute Of Technology | Method of targeted gene delivery using viral vectors |
| ES2428067T3 (es) | 2006-07-21 | 2013-11-05 | California Institute Of Technology | Introducción selectiva de genes para la vacunación con células dendríticas |
| ES2657392T3 (es) | 2006-09-26 | 2018-03-05 | Infectious Disease Research Institute | Composición de vacuna que contiene un adyuvante sintético |
| WO2009019612A2 (en) | 2007-08-03 | 2009-02-12 | Institut Pasteur | Lentiviral gene transfer vectors and their medicinal applications |
| US8563523B2 (en) | 2007-09-07 | 2013-10-22 | University Of Georgia Research Foundation, Inc. | Synthetic lipid A derivative |
| RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
| WO2010105251A2 (en) * | 2009-03-13 | 2010-09-16 | Lentigen Corporation | Non-integrating retroviral vector vaccines |
| NZ597804A (en) | 2009-07-24 | 2013-10-25 | Immune Design Corp | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| US8323662B1 (en) | 2012-03-30 | 2012-12-04 | Immune Design Corp. | Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein |
-
2013
- 2013-03-29 NZ NZ700340A patent/NZ700340A/en not_active IP Right Cessation
- 2013-03-29 CN CN201380028044.9A patent/CN104583231B/zh not_active Expired - Fee Related
- 2013-03-29 PT PT13716670T patent/PT2831095T/pt unknown
- 2013-03-29 CA CA2868838A patent/CA2868838C/en active Active
- 2013-03-29 JP JP2015503650A patent/JP2015512263A/ja not_active Withdrawn
- 2013-03-29 MX MX2014011823A patent/MX362699B/es active IP Right Grant
- 2013-03-29 EP EP13716670.8A patent/EP2831095B1/en active Active
- 2013-03-29 EA EA201491813A patent/EA038702B1/ru unknown
- 2013-03-29 KR KR1020147030477A patent/KR102070472B1/ko not_active Expired - Fee Related
- 2013-03-29 BR BR112014024449A patent/BR112014024449A2/pt active Search and Examination
- 2013-03-29 SG SG11201406162UA patent/SG11201406162UA/en unknown
- 2013-03-29 DK DK13716670.8T patent/DK2831095T3/en active
- 2013-03-29 ES ES13716670T patent/ES2707288T3/es active Active
- 2013-03-29 WO PCT/US2013/034640 patent/WO2013149167A1/en not_active Ceased
- 2013-03-29 AU AU2013237900A patent/AU2013237900B2/en not_active Ceased
- 2013-03-29 EP EP18200744.3A patent/EP3480316B1/en active Active
-
2014
- 2014-09-23 IL IL23483814A patent/IL234838B/en active IP Right Grant
- 2014-10-03 ZA ZA2014/07174A patent/ZA201407174B/en unknown
-
2017
- 2017-12-28 JP JP2017254078A patent/JP2018046860A/ja not_active Withdrawn
-
2019
- 2019-07-16 US US16/513,263 patent/US10993999B2/en not_active Expired - Fee Related
- 2019-12-25 JP JP2019234349A patent/JP2020072689A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512263A5 (enExample) | ||
| CA2768938C (en) | Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein | |
| Zhang et al. | Adenoviral vector-based strategies against infectious disease and cancer | |
| JP7735344B2 (ja) | 疾患の予防および／または治療における使用のためのワクチン | |
| JP2013500015A5 (enExample) | ||
| Hel et al. | Potentiation of simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cell responses by a DNA-SIV and NYVAC-SIV prime/boost regimen | |
| Carnero et al. | Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses | |
| Grasso et al. | Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein | |
| Otten et al. | Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins | |
| McGettigan et al. | Functional human immunodeficiency virus type 1 (HIV-1) Gag-Pol or HIV-1 Gag-Pol and env expressed from a single rhabdovirus-based vaccine vector genome | |
| Ferrantelli et al. | DNA vectors generating engineered exosomes potential CTL vaccine candidates against AIDS, hepatitis B, and tumors | |
| MD3390430T2 (ro) | Antigenele virusului imunodeficienței umane, vectori, compoziții și metode de utilizare ale acestora | |
| Ku et al. | Use of lentiviral vectors in vaccination | |
| CA2918585A1 (en) | Consensus/ancestral immunogens | |
| Schweneker et al. | Recombinant modified vaccinia virus Ankara generating Ebola virus-like particles | |
| US20150182617A1 (en) | Glycoproteins for pseudotyping lentivectors | |
| Uhlig et al. | Lentiviral protein transfer vectors are an efficient vaccine platform and induce a strong antigen-specific cytotoxic T cell response | |
| Chapman et al. | Heterologous prime-boost vaccination with DNA and MVA vaccines, expressing HIV-1 subtype C mosaic Gag virus-like particles, is highly immunogenic in mice | |
| Norton et al. | Recent advances in lentiviral vaccines for HIV-1 infection | |
| Di Bonito et al. | Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein | |
| Yan et al. | Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine | |
| Lescaille et al. | Efficacy of DNA vaccines forming e7 recombinant retroviral virus-like particles for the treatment of human papillomavirus-induced cancers | |
| Schoenly et al. | Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform “spotty business” | |
| JP2008511334A (ja) | クレードＡ／Ｇ、クレードＢ、およびクレードＣ改変ＨＩＶｅｎｖ、ｇａｇ、およびｐｏｌ遺伝子を発現する組換えＭＶＡウイルス | |
| Nkolola et al. | Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa |